Full-Time

R&D Engineer

Medical Device

Spirair

Spirair

11-50 employees

Minimally invasive ENT nasal implants

Compensation Overview

$100k - $120k/yr

No H1B Sponsorship

South San Francisco, CA, USA

Hybrid

Hybrid work arrangement in South San Francisco.

Bachelor's

Category
Biology & Biotech (1)
Required Skills
Word/Pages/Docs
Product Design
SolidWorks
Excel/Numbers/Sheets

Get referred to Spirair

See people who can refer or advise you

Requirements
  • A Bachelor’s degree in Engineering or equivalent is preferred.
  • Two to five years of research and development experience is preferred.
  • Proficiency in SolidWorks for solid models and dimensioned drawings is required.
  • Good documentation skills are required.
  • The ability to multitask and prioritize flexibly in a startup environment is required.
  • Proficiency in Microsoft Word, Excel, and PowerPoint is required.
  • Legal authorization to work in the United States is required.
Responsibilities
  • Design and implement new methodologies, materials, machines, processes, or products.
  • Develop new concepts from initial design through market release.
  • Ensure design control requirements are met, manage product development timelines, and work with a cross-functional team to commercialize new devices in a timely manner.
  • Design test and assembly fixtures in collaboration with engineering and manufacturing.
  • Test designs to validate that they function as intended, including generating and reviewing test protocols, and make design modifications to meet specific market needs.
  • Participate in animal and cadaver feasibility studies as needed throughout the development process to ensure desired functionality.
  • Perform verification testing to establish that new devices meet design input specifications.
  • Develop tools to accompany marketed devices when required.
  • Create detailed documentation throughout the stages of research and development.
  • Work with manufacturing and production as required to ensure product manufacturability.
  • Provide technical support for regulatory, clinical, or sales efforts when required.
  • Participate in and contribute to idea generation, including brainstorming and intellectual property development.
  • Interface with suppliers and customers, including physicians, as required.

Spirair develops minimally invasive ENT medical devices. Its SeptAlign system uses a bioabsorbable implant to straighten minor nasal septal deviations in an in-office procedure under local anesthesia, with the implant dissolving in about six months after the cartilage holds its new shape. In 2025 it added TurbAlign to separate the middle turbinate from the nasal wall to aid healing after sinus surgery. The company sells these devices to ENT professionals and differentiates itself by tissue-preserving implants for office-based correction, aiming to improve nasal airway outcomes with less invasive options and shorter recovery.

Company Size

11-50

Company Stage

N/A

Total Funding

N/A

Headquarters

South San Francisco, California

Founded

N/A

Get referred to Spirair

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • TurbAlign won FDA 510(k) clearance on July 11, 2025.
  • Spirair posted Sr. R&D Engineer jobs in May and July 2026.
  • SEC filings show $24.7 million sold in a $28.2 million offering.

What critics are saying

  • Spirair reported no revenues in its March 2026 Form D amendment.
  • ENT adoption can stall if surgeons prefer established septoplasty and sinus workflows.
  • If reimbursement lags, Spirair burns cash before scaling, threatening company survival.

What makes Spirair unique

  • SeptAlign became FDA-cleared in 2024 as a first minimally invasive NSD therapy.
  • Bioabsorbable implants enable office-based ENT procedures under local anesthesia, not hospital septoplasty.
  • TurbAlign extends Spirair into a broader, implant-based ENT product platform.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

16%

1 year growth

16%

2 year growth

21%
Intelligence360 News
Sep 12th, 2025
Spirair Raises $23.6M in New Funding

Spirair has filed a notice with the U.S. SEC for an exempt offering of securities to raise up to $23.6 million in new funding. This filing is required under federal securities law for companies selling securities without registration under the Securities Act of 1933, using exemptions like Rule 504 or 506 of Regulation D. The notice must be filed within 15 days of the first sale. Spirair specializes in minimally invasive solutions for ENT care.